Last10K.com

Ekimas Corp (ASNB) SEC Filing 10-K Annual Report for the fiscal year ending Wednesday, March 31, 2021

Advansource Biomaterials Corp

HISTORY TOOLS
CIK: 1499961 Ticker: ASNB
Document and Entity Information - USD ($)
$ in Thousands
12 Months Ended
Mar. 31, 2021
Sep. 22, 2021
Sep. 30, 2020
Cover [Abstract]   
Entity Registrant NameEKIMAS Corp  
Entity Central Index Key0001011060  
Document Type10-K  
Document Period End DateMar. 31, 2021  
Amendment Flagfalse  
Current Fiscal Year End Date--03-31  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusNo  
Entity Interactive Data CurrentNo  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Business Flagtrue  
Entity Emerging Growth Companyfalse  
Entity Shell Companytrue  
Entity Public Float  $ 425
Entity Common Stock, Shares Outstanding 28,262,371 
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2021  

View differences made from one year to another to evaluate Advansource Biomaterials Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Advansource Biomaterials Corp.

Continue

Assess how Advansource Biomaterials Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Advansource Biomaterials Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Balance Sheets
Balance Sheets (Parenthetical)
Statements Of Cash Flows
Statements Of Operations
Statements Of Stockholders' Equity (Deficit)
Asset Sale And Discontinued Operations
Asset Sale And Discontinued Operations (Details Narrative)
Asset Sale And Discontinued Operations (Tables)
Asset Sale And Discontinued Operations - Schedule Of Components Of Assets Held-For-Sale (Details)
Asset Sale And Discontinued Operations - Schedule Of Discontinued Operations (Details)
Asset Sale And Discontinued Operations - Schedule Of Transaction Costs Incurred (Details)
Benefit Plans And Employment Agreements Of Executive Officers
Benefit Plans And Employment Agreements Of Executive Officers (Details Narrative)
Business Description
Business Description (Details Narrative)
Concentration Of Credit Risk And Major Customers
Concentration Of Credit Risk And Major Customers (Details Narrative)
Contingencies
Income Taxes
Income Taxes (Details Narrative)
Income Taxes (Tables)
Income Taxes - Schedule Of Reconciliation Of Effective Tax Rate (Details)
Income Taxes - Schedule Of Significant Components Of Deferred Tax Assets (Details)
Income Taxes - Schedule Of Unused Net Operating Loss And Tax Credit Carryforwards (Details)
Liquidity And Going Concern
Liquidity And Going Concern (Details Narrative)
Promissory Notes
Promissory Notes (Details Narrative)
Related Party Transactions
Related Party Transactions (Details Narrative)
Stock Based Compensation
Stock Based Compensation (Details Narrative)
Stock Based Compensation (Tables)
Stock Based Compensation - Schedule Of Black-Scholes Pricing Model Assumptions (Details)
Stock Based Compensation - Schedule Of Stock Option Activity (Details)
Stockholders' Equity
Stockholders' Equity (Details Narrative)
Subsequent Events
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Advansource Biomaterials Corp provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Ticker: ASNB
CIK: 1011060
Form Type: 10-K Annual Report
Accession Number: 0001493152-21-023342
Submitted to the SEC: Wed Sep 22 2021 1:11:55 PM EST
Accepted by the SEC: Wed Sep 22 2021
Period: Wednesday, March 31, 2021
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/asnb/0001493152-21-023342.htm